Monday, 19 February 2018 - 8:50
  • it
  • de
  • en
  • fr

Top stories

News of the week

Gilead wins appeal against Merck & Co. and saves $2.54bn

A judge in the federal court in Delaware has ruled in favor of Gilead in an appeal trial concerning patent issues against Merck & Co.. Specifically, the judge has held invalid Merck & Co.’s patent protecting a hepatitis C treatment,…

Approvals

Procedures / New drug and device authorizations / Recommendations

Johnson & Johnson’s Erleada approved for prostate cancer treatment

Johnson & Johnson has obtained the FDA approval for Erleada (apalutamide) in patients with non-metastatic 
prostate cancer, developing despite hormonal therapy. In fact, Erleada is the first treatment approved for this cancer type. Erleada enters into direct competition with Xtandi…

Companies

Healthcare market news

Gilead wins appeal against Merck & Co. and saves $2.54bn

A judge in the federal court in Delaware has ruled in favor of Gilead in an appeal trial concerning patent issues against Merck & Co.. Specifically, the judge has held invalid Merck & Co.’s patent protecting a hepatitis C treatment,…

Chemistry

Market and Technology

Saudi Aramco partners with Russia-based Sibur

Russian website Prime has reported that Russia-based chemical group Sibur and Saudi Arabia-based Saudi Aramco have entered into a partnership. As part of the agreement, a new elastomers and rubber production facility will be built in Saudi Arabia. The companies…

2D materials fit for business?

Sabic purchases 25% in Clariant

M&A

Mergers & Acquisitions

Crispr Therapeutics: the Swiss biotech raising everyone’s expectations

The recent success of CRISPR technology has brought benefit to the Switzerland-based biotech Crispr Therapeutics, which is attracting attention from investors and competitors. The company’s shares have risen over 70% since the start of the year, and 121% over the…

Nutraceuticals

Food supplements

Asthma, evidences of benefit from vitamin D in The Lancet Respiratory Medicine

The review The Lancet Respiratory Medicine has reported the results from a research conducted by the Queen Mary University of London, demonstrating that oral vitamin D, associated to the standard therapy for asthma, can help halve the risk of asthma…

Pathology

Latest developments

Japan-based Shionogi develops powerful drug to treat influenza

Japan-based pharmaceutical group Shionogi has reported that it has developed a therapy eliminating the A and B influenza virus in 24 hours with a single dose–a far better result than Roche’s Tamiflu, which requires two doses and a minimum of…

Safety

News on Product Safety

FDA issues warning about Intercept’s Ocaliva after 19 patients died

The FDA has officially warned doctors about the risks from Intercept Pharmaceuticals’ Ocaliva (obeticholic acid), after 19 patients on Intercept’s drug, developed to treat PBC (Primary Biliary Cholangitis) had died. The FDA, anyway, has specified that the deaths have occurred…

Trials

Preclinical Trials / Clinical Trials / Epidemiology

Biogen announces ongoing changes for trials on patients with Alzheimer’s and shares drop 7%

Biogen’s shares (Nasdaq) yesterday fell over 7% as the company announced it plans to recruit 510 new patients for trials aimed at testing aducanumab on patients with Alzheimer’s disease, because it has detected high variability in the data collected so…